Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pentagamavunon-1 (PGV-1) is an oral Curcumin analog that effectively induces apoptosis through multiple molecular mechanisms. It primarily targets and inhibits key angiogenic factors, including cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF), which play crucial roles in mediating cell proliferation and survival. Additionally, PGV-1 possesses the ability to inhibit the activation of NF-κB, further enhancing its apoptotic effects. [1]
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 295 | 5日内发货 | ||
5 mg | ¥ 497 | 5日内发货 | ||
10 mg | ¥ 828 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 5日内发货 |
产品描述 | Pentagamavunon-1 (PGV-1) is an oral Curcumin analog that effectively induces apoptosis through multiple molecular mechanisms. It primarily targets and inhibits key angiogenic factors, including cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF), which play crucial roles in mediating cell proliferation and survival. Additionally, PGV-1 possesses the ability to inhibit the activation of NF-κB, further enhancing its apoptotic effects. [1] |
体外活性 | Pentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 μM) enhances cytotoxic effect of 5-FU on WiDr cells [1]. Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 μM) shows different effects on cell cycle progression and induces G2/M arrest [1]. Cell Viability Assay [1]. Cell Line: Human colon carcinoma WiDr. Concentration: 1, 2.5, 5, 7.5, 10, 15, and 20 μM. Incubation Time: 6, 12, 24, and 48 hours. Result: Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. Cell Cycle Analysis [1]. Cell Line: WiDr cells. Concentration: 1, 2.5, 5, and 10 μM. Incubation Time: 24 h. Result: The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively. |
体内活性 | Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity [1]. Animal Model: Human cancer cells in a xenograf mouse model [2]. Dosage: 20mg/kg. Administration: P.O. every 2 days for 20 days. Result: Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells. |
分子量 | 348.43 |
分子式 | C23H24O3 |
CAS No. | 27060-70-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pentagamavunon-1 27060-70-4 Inhibitor inhibitor inhibit